Alcoholics face a laundry list of potential health problems, including an increased risk of skin infections due to a compromised immune response. Now a team of investigators has highlighted the well-known link between alcoholism and skin infections, while pointing to a therapeutic target that could reduce or eliminate the risk of infection.
The European Respiratory Society and American Thoracic Society have joined forces to highlight what we don't know about COPD in order to steer future research programs in the right way.
It turns out that mice are much better equipped than humans when it comes to regenerating and repairing the liver. A group of investigators at UC Davis note that the main difference is that rodents can rely on mouse PPARα that is much more efficient than human PPARα. And they've tested another protein, fibroblast growth factor 21, that could make up the difference for humans.
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
A pair of researchers at the University of Michigan Comprehensive Cancer Center say they have been making fresh progress on a new therapeutic approach to a relatively rare form of acute leukemia. And the biotech that in-licensed the work heralded the latest advance as another indication of the promise it holds for the cancer field.
A year after Concert Pharmaceuticals translated its work using deuterium to amp up the efficacy and stability of drugs into an upsized $84 million IPO, the biotech says it's completed a positive animal study on a new treatment designed to prevent seizures.
In the world of Alzheimer's drug research, there's no lack of certainty among leading researchers. There's just no consensus on what causes the disease or how to treat it.
A team of investigators from Duke and the NUS Graduate Medical School in Singapore says they've come up with a novel one-two punch directed against mutant RAS that they believe could have broad potential in fighting cancers.
The African ape population has played a key role in the enduring threat posed by ebolavirus. Now a group of investigators say they have some new animal data that suggest a CMV-based vaccine could spark the spread of a protective "disseminating" virus that may prevent the threat in the first place.
Scientists at the Scripps Research Institute say they've identified an enzyme necessary for maintaining the stability of hematopoietic stem cells.
Zeroing in on an enzyme that is over-expressed in brain tumor cells, two investigators at Houston Methodist say they have developed a new treatment for gliomas that has cleared its preclinical testing and should be ready for human testing within the next one to two years.
Bypassing the traditional delivery technologies for antibiotics, European investigators say they successfully tested the use of nanoparticles in delivering antibiotics for respiratory infections, slipping through biological barriers and zeroing in better on the target.
Up until now, most of the work focused on the amyloid beta theory on Alzheimer's has concentrated on drugs that can clear the toxic protein clusters many believe trigger brain damage and memory loss. But a team in Australia has been winning headlines around the world after demonstrating in mice that they can do the same thing with an ultrasound approach.
The promise of new gene editing technology called CRISPR has been lighting up a string of new lab experiments around the world.
A group of investigators at the University of Chicago says they've found a drug that can guard myelin-producing cells, offering a possible new route to guarding against multiple sclerosis. And this is one therapy that has already been through the approval process.
An oncologist at the University of Minnesota has devised a "homegrown" bispecific antibody that binds to both CD19 and CD22, proteins found on the surface of B-cell blood cancers, and drops a toxic payload on the targeted cells. In a Phase I trial with 10 evaluable patients with treatment resistant pre-B acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma, two had a durable response, with one complete remission. And that is setting the stage for a mid-stage study of a drug that has been pushed this far largely with private donations.
Psoriasis has attracted a big pack of rival drug giants anxious to be in the lead with a new wave of better, targeted therapies for legions of patients. But a team of investigators at Rockefeller University say they just scored early-stage data on a new drug from Boehringer Ingelheim that promises to offer a potential cure with a more durable therapy.
The intravenous administration of monocytic myeloid-derived suppressor cells, or M-MDSCs, proved promising in treating rheumatoid arthritis in mice, inhibiting T cell proliferation, as well as B cell proliferation and antibody production.
By turning their backs on years of research work on fighting herpes viruses, Howard Hughes Medical Institute investigators at Albert Einstein College of Medicine say they were able to design a radically different type of vaccine that proved effective in mice. And they say the same vector has promise in fighting diseases like HIV and tuberculosis.
Scientists at the Salk Institute say they have achieved some remarkable results in using the new CRISPR gene editing technology to chop up active and dormant HIV, potentially opening the door to a new approach that could ultimately free patients from the meds needed to keep the virus at bay while also preventing the spread of infection in the first place.